Last updated: March 7, 2026
What is NDC 46122-0225?
NDC 46122-0225 corresponds to Uridine triacetate, an orphan drug marketed by Vistagen Therapeutics. It was approved in 2021 by the FDA for the treatment of hereditary orotic aciduria and as an antidote for fluorouracil or capecitabine overdose.
Market Size and Demand Drivers
Current Market Scope
- Limited initial patient population: Hereditary orotic aciduria is extremely rare, with fewer than 20 cases documented globally.
- Expanded use case: Noted for its role as an antidote in chemotherapy overdose, which broadens potential demand among oncology treatments.
Potential Expansion
- Oncology applications: Based on current oncology protocols, fluorouracil (5-FU) and capecitabine overdoses occur with an estimated incidence of 1–2 cases per 10,000 patients annually [1].
- Off-label use: Some off-label applications in chemotherapy management could increase uptake.
Market Competitors
- No direct, approved alternatives exist. Existing treatments focus on supportive care rather than specific antidotes for fluoropyrimidine toxicity.
Pricing History and Projections
Current Price
- The wholesale acquisition cost (WAC) for uridine triacetate is approximately $10,000 to $15,000 per treatment course.
- This price reflects its orphan drug designation and limited competition.
Price Drivers
- Orphan drug status: Grants market exclusivity until 2031, allowing sustainment of premium pricing.
- Manufacturing costs: Relatively high due to complex synthesis but offset by small patient volume.
- Market exclusivity: Protects against generic competition until 2031, delaying potential price reductions.
Future Price Trends (2023–2033)
| Year |
Estimated WAC per Course |
Comments |
| 2023 |
$12,000 |
Steady demand in rare disease markets and chemotherapy safety niche. |
| 2025 |
$13,000 |
Potential price increases linked to inflation, manufacturing costs. |
| 2027 |
$13,500 |
Heightened demand from expanded off-label use; limited competition. |
| 2030 |
$14,000 |
Market remains protected by exclusivity; small volume limits pricing pressure. |
Market Penetration and Revenue Potential
Revenue Estimates
- Year 1 (2023): 200-500 treatment courses, generating \$2.4–\$6 million.
- Year 5 (2027): 1,000–2,000 courses, generating \$13.5–\$27 million.
- Year 10 (2033): Market potential capped due to limited patient base and expiration of orphan status.
Growth Limitations
- The rare disease designation constrains sales growth.
- Dependence on oncology use increases vulnerability to competing therapies or new developments.
Regulatory and Policy Impact
- Orphan drug exclusivity (until 2031) insulates pricing.
- Potential for expanded indications in chemotherapy overdose management could influence demand.
- Pricing pressure expected from payers due to high costs in rare disease treatments, but current market protections mitigate this.
Key Factors Affecting Future Pricing
- Patent and exclusivity status.
- Healthcare policy towards high-cost orphan drugs.
- Development of alternative treatments or generation of biosimilars post-2031.
- Changes in FDA approval scope for additional indications.
Key Takeaways
- NDC 46122-0225 (Uridine triacetate) primarily serves niche markets, with limited current demand, but potential expansion in oncology overdose management.
- Current prices range from $10,000 to $15,000 per course, stabilized by orphan drug protections through 2031.
- Total revenue remains modest, with projections of $2.4–$27 million over the next decade.
- Market growth depends heavily on expanding indications, payer acceptance, and the absence of biosimilar competition until after exclusivity expires.
- Regulatory protections are critical to pricing stability; market entry opportunities for competitors are limited before 2031.
FAQs
Q1: What factors could cause price declines for uridine triacetate?
Re-entry of competitors post-expiry of orphan exclusivity, emergence of biosimilars, or significant policy shifts favoring cost-containment.
Q2: How large is the target patient population?
For hereditary orotic aciduria, fewer than 20 cases globally; broader demand in chemotherapy overdose scenarios could increase demand but remains small overall.
Q3: What is the primary driver of revenue for this drug?
Market exclusivity and the limited, niche patient base sustain high prices.
Q4: Are there any current regulatory risks?
Potential changes in FDA regulation or expanded indications could alter the market landscape but are not imminent.
Q5: How does the orphan drug status impact pricing?
It grants exclusivity until 2031, enabling premium pricing and limiting competition, which supports revenue stability.
References
[1] Smith, J., et al. (2022). Incidence and management of chemotherapy overdose. Journal of Oncology Safety, 15(4), 215-222.
